The sales and distribution agreement was with Tri-State Biologics, which provides instruments and implants to hospitals in Greater New York City, Philadelphia, New Jersey, Connecticut, and Massachusetts.
Bioretec plans to sign more local sales agreements in the U.S. as part of the next phase of RemeOs traume screw commercialization.
The RemeOs product line is based on a magnesium alloy and hybrid composite, and implants are resorbed and replaced by bone.
At the Becker's 23rd Annual Spine, Orthopedic and Pain Management-Driven ASC + The Future of Spine Conference, taking place June 11-13 in Chicago, spine surgeons, orthopedic leaders and ASC executives will come together to explore minimally invasive techniques, ASC growth strategies and innovations shaping the future of outpatient spine care. Apply for complimentary registration now.
